Medicilon Assist – New progress in the field of NASH! Hepadin's HPD001 is about to start clinical trials in the U.S.

Recently, HPD001, an original innovative drug independently developed by Guangzhou Hapedin, will start clinical trials in the United States. The drug was approved by the FDA for clinical research last year, and the indication is non-alcoholic steatohepatitis (NASH).

Medicilon provided pharmacology research during the research and development of HPD001, which laid a solid foundation for the drug to enter clinical trials.

NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), accompanied by inflammation and liver fibrosis, which can directly lead to cirrhosis and liver cancer. At present, there are no drugs approved for the treatment of NASH in the world, and patients have limited treatment options. HPD001 is a non-bile acid structure, high-efficiency partial FXR agonist. This target is currently the only NASH therapeutic target that has been verified by phase III clinical trials. While HPD001 has shown superior curative effect, it also shows good safety. The drug is expected to solve the chronic disease of NASH.

In the research and development of HPD001, the Medicilon Pharmacology Department relied on the non-alcoholic fatty liver disease (NAFLD) model and liver fibrosis model to accurately simulate typical symptoms such as non-alcoholic steatohepatitis and liver cirrhosis. Pharmacology tests help it to quickly obtain FDA approval, and actively carry out NMPA clinical application and clinical trial preparation in China. Strive for the unfinished business of human health. Since its establishment in 2004, Medicilon has always focused on the unmet needs of preclinical research and development. Over the past 17 years, Medicilon’s Pharmacology Department has driven development with technological innovation, and has gained experience in research and development. It has an SPF-level animal room that meets international standards, and has established more than 160 animal models for the research and evaluation of new non-tumor target drugs.

In addition to metabolic diseases such as NASH, the drug evaluation system of Medicilon also covers neuropsychiatric diseases, inflammatory and immune system diseases, cardiovascular & blood system diseases, digestive system diseases, etc., which can meet the current hot diseases such as Alzheimer's The research and development needs of new drugs for diseases such as disease, inflammation and immunity.